222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-140050642014-09-012014-08-06A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stageInvestigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis chronic kidney disease1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;Shanghai University of T.C.MNULLRecruiting1860Both1:50;2:50;China
2NCT01845688November 201129/4/2013Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous NephropathyEfficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical StudyIdiopathic Membranous NephropathyDrug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo GranulewanglinNULLActive, not recruiting18 Years70 YearsBoth72N/AChina
3NCT00814255December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada